Genes

Abbott's rapidly growing molecular diagnostics business provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. The business includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA.

Germinated from assets acquired in 2003 from GSK, Affinium's antibacterial programs now include a broad base of intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors, genes, proteins, assays, crystal structures and combinations of FabInhibitors with known antibiotics. These assets represent a new class of antibiotics with a unique mechanism of action, targeting an unexploited pathway, bacterial fatty acid biosynthesis.